Target Price | $172.32 |
Price | $63.82 |
Potential |
170.01%
register free of charge
|
Number of Estimates | 22 |
22 Analysts have issued a price target Sarepta Therapeutics, Inc. 2026 .
The average Sarepta Therapeutics, Inc. target price is $172.32.
This is
170.01%
register free of charge
$215.00
236.88%
register free of charge
$75.00
17.52%
register free of charge
|
|
A rating was issued by 24 analysts: 21 Analysts recommend Sarepta Therapeutics, Inc. to buy, 2 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Sarepta Therapeutics, Inc. stock has an average upside potential 2026 of
170.01%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 1.90 | 3.14 |
52.97% | 64.87% | |
EBITDA Margin | 14.30% | 37.27% |
185.10% | 160.64% | |
Net Margin | 11.92% | 31.63% |
126.37% | 165.32% |
21 Analysts have issued a sales forecast Sarepta Therapeutics, Inc. 2025 . The average Sarepta Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Sarepta Therapeutics, Inc. EBITDA forecast 2025. The average Sarepta Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Sarepta Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Sarepta Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 2.34 | 10.23 |
140.34% | 337.18% | |
P/E | 6.88 | |
EV/Sales | 2.17 |
13 Analysts have issued a Sarepta Therapeutics, Inc. forecast for earnings per share. The average Sarepta Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Sarepta Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Scotiabank |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
Deutsche Bank |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
Needham |
Locked
➜
Locked
|
Locked | Mar 18 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Mar 18 2025 |
Scotiabank |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
Analyst Rating | Date |
---|---|
Locked
Scotiabank:
Locked
➜
Locked
|
Mar 20 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 19 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Mar 19 2025 |
Locked
Deutsche Bank:
Locked
➜
Locked
|
Mar 19 2025 |
Locked
Needham:
Locked
➜
Locked
|
Mar 18 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Mar 18 2025 |
Locked
Scotiabank:
Locked
➜
Locked
|
Mar 07 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.